Pharma Leader Series: Top 25 Biosimilar Drug Manufacturers 2015-2025

Attention: There is an updated edition available for this report.

Pharma Leader Series: Top 25 Biosimilar Drug Manufacturers 2015-2025

Biosimilar drug producers – your guide to those companies’ activities and prospects

What does the future hold for makers of biosimilar medicines? Discover those companies’ outlooks from 2015. You see results, trends, opportunities and revenue forecasting.

Visiongain’s new study analyses 25 leading developers, producers and marketers of biosimilars. That work also covers other firms, including big pharma companies entering that industry. There you assess potentials of established competitors and emerging players.

That analysis is for everyone interested in the future of biopharmaceuticals. Biosimilar drug sales expand fast, and that market holds vast potential. See now how you can benefit.

Forecasts and other data to help you stay ahead in knowledge of those biological drugs

In that updated report you find analytical profiles of the top 25 biosimilar drug companies worldwide. There you analyse products, sales results, R&D and market shares. See qualitative analyses too for those biologics, and discussions of many other relevant firms.

There gain 61 tables, 43 charts and two interviews with companies. That work lets you assess the most lucrative parts of the industry for biosimilar drugs (follow-on biologics or subsequent entry biologics). Explore the future of those recombinant therapeutic proteins.

See how you can benefit your research, analyses and decisions on those protein-based medicines. Also save time. And avoid struggles to find business information. Instead stay ahead for knowledge on the present and future of those biological drugs.

So explore changes that affect the biologics industry from 2015. And the following sections explain what you get in our investigation.

Therapy classes giving biosimilars – what’s happening there?

First our new study discusses biotechnological agents giving biosimilars. It shows that market’s advances, results and potentials.

There find prospects for developments and competition in these eight biosimilar classes:

  • Erythropoietins (EPO)
  • Insulin
  • Granulocyte-colony stimulating factor (G-CSF)
  • Somatropins
  • Interferons
  • Monoclonal antibodies (therapeutic mAbs)
  • Follicle-stimulating hormone (FSH)
  • Other follow-on protein therapies.
Analyses include a grouped revenue forecast at world level to 2025 for biosimilar medicines. See what’s possible for those competitors of blockbuster biological drugs.

Molecules giving rise to biosimilars – explore where progress occurs

Then that report lets you assess biosimilar competition for these five therapeutic agents, including research and development:
  • Adalimumab
  • Infliximab
  • Etanercept
  • Darbepoetin alpha
  • Rituximab.
Also explore original products such as Humira, Remicade, Enbrel, Aranesp and Rituxan, as well as relevant activities affecting other treatments in human healthcare.

Vast opportunities remain for biosimilars, with our study predicting high, rapid market expansion from 2015 to 2025. See what’s possible. And discover where best prospects exist and which companies are most likely to prosper.

That way, gain data and other knowledge to benefit your reputation for commercial insight, especially on products, technologies, activities and potentials of those organisations.

Leading biosimilar drug companies – see what they’re doing, including their outlooks

In particular our survey analyses 25 leading biosimilar specialists, including these firms:
  • Sandoz
  • Teva Pharmaceutical Industries
  • Hospira
  • Celltrion
  • LG Life Sciences
  • Biocon
  • Mylan
  • Dr. Reddy’s Laboratories.
There see possibilities for that technology and business. And, besides those 25 companies, you also investigate other organisations relevant to that market. They include Eli Lilly, Merck & Co., Bristol-Myers Squibb, Amgen, Pfizer, Merck KGaA and Boehringer Ingelheim.

That way you assess large pharma corporations and smaller companies. You find analysis of 27 other firms based in North America, Asia – esp. Japan, India and China – Western Europe, Latin America, Central and Eastern Europe (CEE). See progress and possibilities.

So explore who shapes the biosimilars market and how, well as policies and other forces influencing those companies and their industry, including its revenues and profits.

Issues affecting developers, producers and sellers of those pharmaceuticals

Our investigation also explains influences and events affecting the biosimilars industry and market from 2015, including these forces:
  • Biosimilar approval pathways and other regulations
  • Emerging national markets and expanding therapeutic needs worldwide
  • Healthcare savings, including governmental support for that industry
  • Big pharma entering that market – effects on participants, looking ahead.
And these effects, among others:
  • Patent expiries and resulting opportunities for next generation products
  • Innovative biologics, including biobetters, and their influence on biosimilars
  • R&D helping expansion of that market – new technologies and commercial opportunities, including potential for vaccines.
There you examine political, economic, social and technological questions, assessing commercial outlooks. And also strengths, weaknesses, opportunities and threats. Explore what stimulates and restrains participants in that industry and affects their results.

Developing and developed national markets will prove important for biosimilar drug sales from 2015 to 2025. Discover what the future holds and the expected gains.

Ways Pharma Leader Series: Top 25 Biosimilar Drug Manufacturers 2015-2025 helps you

Our new study helps your work in these five main ways:
  • Profiles of 25 leading biosimilar companies and other organisations – assess product ranges, results, strategies, technologies and outlooks
  • R&D for biosimilars – see activities by medicine and company, finding what’s happening in that industry, esp. hearing its technological and commercial potential
  • Competition and opportunities – explore what affects the biosimilars market, finding what shapes its future, esp. prospects for sustaining and developing business
  • Actions of established, rising and emerging companies – discover firms’ capabilities, advances and outlooks, also getting opinions from two interviews
  • Forecasting of revenues to 2025 for that industry at world level – investigate overall sales potential there, helping you understand opportunities and stay ahead.
Data and analyses found nowhere else – discover the future of those biologics

Our work gives independent analysis. There you get competitive intelligence found only in our report. You discover the most promising market segments, and companies most likely to succeed.

With that investigation you’re less likely to fall behind in knowledge. Find there how you could benefit your research, analysis and decisions. Also see how to save time and gain in recognition for understanding the biological drugs market, helping your influence.Please Note: Prior to initiating fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.

The publisher is using a password system to access all reports. Single user and departmental licenses expires after 12 month period. In the case of departmental site license purchases, the publisher requires all email addresses for the licensed users prior to fulfilment.

Companies Listed

Abbott Laboratories
Aragen Bioscience
ASKA Pharmaceuticals
Baxter International
Beijing SL Pharmaceutical
Bio Technology General Corporation
Biogen Idec.
Biolab Sanus Farmacêutica
Biotech GmbH
Biovel Life Sciences
BioXpress Therapeutics
Boehringer Ingelheim
Brazil’s National Economic Development Bank (BNDES)
Brazilian Ministry of Health
Brazilian Ministry of Science and Technology (MST)
Bristol-Myers Squibb
Catalent Pharma Solutions
China Israel Value Capital
Chongqing Fochon Pharmaceutical Research Co.
Coherus Biosciences
Comisión Federal para la Protección contra Riesgos Sanitarios (Cofepris)
Committee for Medicinal Products for Human Use (CHMP)
Competitions Commission of India (CCI)
Daiichi Sankyo
Dainippon Sumitomo Pharma
Dong-A Pharmaceuticals
Dr. Reddy's Laboratories
Drugs Controller General of India
Egis Pharmaceuticals
Eli Lilly
Emcure Pharmaceuticals
Epirus Pharmaceuticals
European Medicines Agency (EMA)
Financier of Studies and Projects (FINEP)
Finox Biotech
Food and Drug Administration (FDA)
Forwell Biopharm
Fosun Pharma
Fuji Pharma
Fujifilm Kyowa Kirin Biologics
Gan & Lee Pharmaceutical
Generex Biotechnology Corporation
German Remedies
Germonta Holdings
Hanwha Chemical
Hetero Drugs
Hualida Biotech
Human Genome Sciences
Impax Laboratories
Indian Clinical Trials Registry (CTRI)
Innovent Biologics
Intas Biopharmaceuticals
Intas Pharmaceuticals
Itero Biopharmaceuticals
Janssen Biotech
Japan's Ministry of Health, Labour and Welfare
JCR Pharmaceuticals
Johnson & Johnson
Korean Food and Drug Administration (KFDA)
Kwizda Pharmaceutical
Kyowa Hakko Kirin
Lallemand-Institut Rosell
LG Life Sciences
Libbs Farmacêutica
Marvel Life Sciences
Medice Arzneimittel Pütter GmbH & Co. KG
Meiji Seika Pharmaceuticals
Merck & Co.
Merck KGaA
Merck Serono
Mindar Holdings
Mitsubishi Tanabe
MJ Biopharm
MJ Bioton Life Sciences
Mochida Pharmaceutical
Momenta Pharmaceuticals
National Autonomous University of Mexico (UNAM)
National Council for Science and Technology (CONACyT)
Nippon Kayaku
Novo Nordisk
Orygen Biotecnologia
Oswaldo Cruz Foundation
Qilu Pharmaceutical
Reliance Life Sciences
Richter-Helm BioTec GmbH & Co. KG
Samsung Bioepis
Samsung BioLogics
Savient Pharmaceuticals
Selecta Biosciences
Shanghai Celgen Biopharmaceutical
Shanghai CP Guojian
Shanghai Fosun Pharmaceuticals
Shanghai Henlius Biotech Co.
Shanghai Lansheng Guojian Pharmaceutical Co. Ltd
Shanghai Pharmaceutical Group
Shantha Biotechnics
Shreya Life Sciences
Sicor Biotech
Sidus Pharmaceutical Group
STADA Arzneimittel
State's Employees´ Social Security and Social Services Institute (ISSSTE)
Sun Pharmaceuticals
Tat BioTech Holdings Limited
Teva Pharmaceutical Industries
Tonghua Dongbao
União Química
US Centers for Disease Prevention and Control (CDC)
Wanbang Biopharmaceuticals
World Health Organization (WHO)
Xiamen Amoytop Biotech
Zenotech Laboratories
Zhejiang Hisun
Zydus Biovation
Zydus Cadila

1. Report Overview
1.1 Why You Should Read This Report
1.2 How This Report Delivers
1.3 Main Questions Answered by this Analysis
1.4 Who is this Study for?
1.5 Methods of Research and Analysis
1.6 Frequently Asked Questions (FAQs)
1.7 Some Associated Reports
1.8 About Visiongain
2. Introduction to Biologics and Biosimilars
2.1 Biological Drugs - A Definition and Overview
2.2 Biosimilars - A Definition and Overview
2.2.1 Clarifying Biosimilars - Differences from Generics
2.3 Categorising Biologic and Biosimilar Drugs
3. World Biosimilar Drug Market, 2015-2025
3.1 The World Biosimilars Market, 2015
3.2 The World Biosimilars Market Forecast: 2015-2025
3.3 Biosimilars – Realising their Potential, Market Drivers
3.3.1 Biosimilar Approval Pathways and Regulations
3.3.2 Emerging Markets for Biosimilars
3.3.3 Start-up Pressure on Market Leaders
3.3.4 The Patent Cliff for Biologics
3.4 Biosimilars: Market Restraints
3.4.1 Market Fragmentation for Biosimilar Products in Biosimilars Market
3.4.2 Innovative Biologics – Rendering Biosimilars Useless?
3.4.3 Biobetters – A Growing Threat
4. World Biosimilar Submarket, 2015
4.1 Biosimilar Erythropoietins (EPO): Market Overview
4.2 Biosimilar Insulin: Market Overview
4.3 Biosimilar G-CSF: Market Overview
4.4 Biosimilar Somatropins: Market Overview
4.5 Biosimilar Interferons: Market Overview
4.6 Biosimilar Monoclonal Antibodies: Market Overview
4.7 Biosimilar FSH: Market Overview
4.8 Other Biosimilars in the Biosimilars Market: Overview
5. Biologics and Biosimilar Targets – Looking to the Future
5.1 Humira: Product Overview
5.1.1 Adalimumab Biosimilars – Zydus Cadila
5.1.2 Adalimumab Biosimilars – Amgen-Actavis
5.1.3 Adalimumab Biosimilars – Sandoz
5.1.4 Adalimumab Biosimilars – Momenta Pharmaceuticals
5.1.5 Adalimumab Biosimilars – Pfizer
5.1.6 Adalimumab Biosimilars – Boehringer Ingelheim
5.2 Remicade: Product Overview
5.2.1 Infliximab Biosimilar – Epirus Pharmaceuticals & Ranbaxy
5.2.2 Infliximab Biosimilar – Celltrion & Hospira & Alvogen
5.3 Enbrel: Product Overview
5.3.1 Etanercept Biosimilar – Cipla & Shanghai CP Guojian
5.3.2 Etanercept Biosimilar – Daiichi Sankyo & Coherus Biosciences
5.4 Aranesp: Product Overview
5.4.1 Darbepoetin alpha Biosimilar – Dr. Reddy’s Laboratories
5.4.2 Darbepoetin alpha Biosimilar – Cipla & Hetero Drugs Limited
5.4.3 Darbepoetin alpha Biosimilar – Hospira
5.5 Rituxan: Product Overview
5.5.1 Rituximab Biosimilar – Sandoz
5.5.2 Rituximab Biosimilar – Amgen
5.5.3 Rituximab Biosimilar – Boehringer Ingelheim
5.5.4 Rituximab Biosimilar – Dr. Reddy’s Laboratories
5.5.5 Rituximab Biosimilar – Pfizer
5.5.6 Rituximab Biosimilar – Difficulties
6. Top 25 Biosimilar Manufacturers, 2015
6.1 Sandoz – Company Overview & Analysis
6.1.1 Sandoz Biosimilar Products
6.1.2 Sandoz Biosimilars Pipeline & Future Strategies GP2017 – Adalimumab Biosimilar GP2015 – Etanercept Biosimilar GP2013 – Rituximab Biosimilar HX575 – Epoetin alfa Biosimilar EP2006 – Zarzio (Filgrastim Biosimilar)
6.2 Teva – Company Overview & Analysis
6.2.1 Teva Biosimilar Products
6.2.2 Teva Biosimilars Pipeline & Future Strategies Lipefilgrastim (Lonquex)
6.2.3 Teva Biosimilar Reshuffle
6.3 Hospira – Company Overview & Analysis
6.3.1 Hospira Biosimilar Products
6.3.2 Hospira Biosimilars Pipeline & Future Strategies Retacrit Celltrion Partnerships NovaQuest Partnership
6.4 Celltrion – Company Overview & Analysis
6.4.1 Celltrion Biosimilar Products
6.4.2 Celltrion Biosimilars Pipeline & Future Strategies CT-P06 – Trastuzumab Biosimilar CT-P15 – Cetuximab Biosimilar CT-P05 – Etanercept Biosimilar CT-P14 – Palivizumab Biosimilar CT-P17 – Adalimumab Biosimilar CT-P16 – Bevacizumab Biosimilar
6.5 LG Life Sciences – Company Overview & Analysis
6.5.1 LG Life Sciences Biosimilar Products
6.5.2 LG Life Sciences Biosimilars Pipeline & Future Strategies Valtropin LB03002 – Declage TNFMab – Adalimumab Biosimilar TNFCept – Etanercept Biosimilar LBRx – Rituximab Biosimilar
6.6 Biocon – Company Overview & Analysis
6.6.1 Biocon Biosimilar Products
6.6.2 Biocon Biosimilars Pipeline & Future Strategies Biosimilar Lispro & Aspart Biosimilar Canmab/Hertraz Biosimilar Bevacizumab Biosimilar Adalimumab Biosimilar Etanercept Biosimilar Pegylated Filgrastim
6.7 Mylan – Company Biosimilar & Analysis
6.7.1 Mylan Biosimilar Products
6.7.2 Mylan Biosimilars Pipeline & Future Strategies Biosimilar Insulin Glargine Biosimilar Insulin Lispro & Aspart Biosimilar Monoclonal Antibodies
6.8 Qilu Pharmaceutical – Company Overview & Analysis
6.8.1 Qilu Pharmaceutical Biosimilar Products
6.8.2 Qilu Pharmaceutical Biosimilars Pipeline & Future Strategies
6.9 3SBio – Company Overview & Analysis
6.9.1 3SBio Biosimilar Products
6.9.2 3SBio Biosimilars Pipeline & Future Strategies NuPIAO
6.10 Bioton – Company Overview & Analysis
6.10.1 Bioton Biosimilar Products
6.10.2 Bioton Biosimilars Pipeline & Future Strategies
6.11 Dr. Reddy’s Laboratories – Company Overview & Analysis
6.11.1 Dr. Reddy’s Laboratories Biosimilar Products
6.11.2 Dr. Reddy’s Laboratories Biosimilars Pipeline & Future Strategies Merck Serono Collaboration
6.12 Beijing ShuangLu Pharmaceutical – Company Overview & Analysis
6.12.1 Beijing ShuangLu Pharmaceutical Biosimilar Products
6.12.2 Beijing ShuangLu Pharmaceutical Biosimilars Pipeline & Future Strategies
6.13 Shanghai Fosun Pharmaceuticals – Company Overview & Analysis
6.13.1 Shanghai Fosun Pharmaceuticals Biosimilar Products
6.13.2 Shanghai Fosun Pharmaceuticals Biosimilars Pipeline & Future Strategies
6.14 Wockhardt – Company Overview & Analysis
6.14.1 Wockhardt Biosimilar Products
6.14.2 Wockhardt Biosimilars Pipeline & Future Strategies
6.15 STADA Arzneimittel – Company Overview & Analysis
6.15.1 STADA Biosimilar Products
6.15.2 STADA Biosimilars Pipeline & Future Strategies Biosimilar Rituximab Biosimilar Teriparatide
6.16 Probiomed – Company Overview & Analysis
6.16.1 Probiomed Biosimilar Products
6.16.2 Probiomed Biosimilars Pipeline & Future Strategies
6.17 Biosidus – Company Overview & Analysis
6.17.1 Biosidus Biosimilar Products
6.17.2 Biosidus Biosimilars Pipeline & Future Strategies
6.18 Ranbaxy – Company Overview & Analysis
6.18.1 Ranbaxy Biosimilar Products
6.18.2 Ranbaxy Biosimilars Pipeline & Future Strategies
6.19 Dong-A – Company Overview & Analysis
6.19.1 Dong-A Biosimilar Products
6.19.2 Dong-A Biosimilars Pipeline & Future Strategies DA-3031 – Pegylated Filgrastim Biosimilar DA-3803 – hCG Biosimilar DA-3051 – Interferon Beta Biosimilar DA-3030 – Filgrastim Biosimilar DA-3111 – Trastuzumab Biosimilar DA-3808 – Recombinant Factor VIII Biosimilar DA-3880 – Darbepoetin alpha Biosimilar DA-3853 – Etanercept Biosimilar DA-3113 – Adalimumab Biosimilar
6.20 Tonghua Dongbao – Company Overview & Analysis
6.20.1 Tonghua Dongbao Biosimilar Products
6.20.2 Tonghua Dongbao Biosimilars Pipeline & Future Strategies
6.21 Reliance Life Sciences – Company Overview & Analysis
6.21.1 Reliance Life Sciences Biosimilar Products
6.21.2 Reliance Life Sciences Biosimilars Pipeline & Future Strategies
6.22 Intas Biopharmaceuticals – Company Overview & Analysis
6.22.1 Intas Biopharmaceuticals Biosimilar Products
6.22.2 Intas Biopharmaceuticals Biosimilars Pipeline & Future Strategies Biosimilar Pegylated Interferon Biosimilar Etanercept Biosimilar Ranibizumab
6.22.3 Overseas Opportunities
6.23 Zydus Cadila – Company Overview & Analysis
6.23.1 Zydus Cadila Biosimilar Products
6.23.2 Zydus Cadila Biosimilars Pipeline & Future Strategies Biosimilar Interferon beta-1b Oncology Biosimilars Inflammation Biosimilars Thrombolytic Biosimilars Fertility Biosimilars
6.24 Shanghai CP Guojian Pharmaceuticals – Company Overview & Analysis
6.24.1 Shanghai CP Guojian Pharmaceuticals Biosimilar Products
6.24.2 Shanghai CP Guojian Pharmaceuticals Biosimilars Pipeline & Future Strategies
6.25 Emcure Pharmaceuticals – Company Overview & Analysis
6.25.1 Emcure Pharmaceuticals Biosimilar Products
6.25.2 Emcure Pharmaceuticals Biosimilars Pipeline & Future Strategies
6.26 Big Pharma – Potential Market Entrants?
6.26.1 Amgen – Biosimilar Business Analysis
6.26.2 Pfizer – Biosimilar Business Analysis
6.26.3 Merck KGaA – Biosimilar Business Analysis
6.26.4 Boehringer Ingelheim – Biosimilar Business Analysis
7. National Overviews of Biosimilar Manufacturers, 2015
7.1 US Biosimilar Manufacturers
7.1.1 Impax Laboratories Inc. – Company Overview & Analysis
7.1.2 Bristol-Myers Squibb – Company Overview & Analysis
7.1.3 Merck & Co. – Company Overview & Analysis
7.1.4 Eli Lilly- Company Overview & Analysis
7.2 Japanese Biosimilar Manufacturers
7.2.1 JCR Pharmaceuticals – Company Overview & Analysis
7.2.2 Nippon Kayaku – Company Overview & Analysis
7.2.3 Fujifilm Kyowa Kirin Biologics – Company Overview & Analysis
7.2.4 Other Companies in Japanese Biosimilars Industry
7.3 EU Biosimilar Manufacturers
7.3.1 BioXpress Therapeutics – Company Overview & Analysis
7.3.2 Medice Arzneimittel Pütter GmbH & Co. KG – Company Overview & Analysis
7.3.3 Finox Biotech – Company Overview & Analysis
7.3.4 Gedeon-Richter – Company Overview & Analysis
7.3.5 Egis Pharmaceuticals – Company Overview & Analysis
7.3.6 Actavis – Company Overview & Analysis
7.4 Emerging Markets for Biosimilars
7.4.1 Brazilian Biosimilar Manufacturers Bionovis – Company Overview & Analysis Orygen Biotecnologia – Company Overview & Analysis Recepta – Company Overview & Analysis
7.4.2 Russian Biosimilar Manufacturers Biocad – Company Overview & Analysis
7.4.3 Indian Biosimilar Manufacturers Shreya Life Sciences – Company Overview & Analysis Cipla – Company Overview & Analysis Shantha Biotechnics – Company Overview & Analysis
7.4.4 Chinese Biosimilar Manufacturers Zhejiang Hisun – Company Overview & Analysis Innovent Biologics – Company Overview & Analysis Shanghai Celgen Biopharmaceutical – Company Overview & Analysis
8. Qualitative Analysis of the Biosimilars Market, 2015-2025
8.1 SWOT Analysis of the Global Biosimilars Industry and Market: 2015-2025
8.1.1 Strengths Savings in Healthcare Costs Strong Pipeline – Innovation and Growth of the Biosimilars Market
8.1.2 Weaknesses R&D Cost – Pricing Companies Out of Biosimilars? Developing Market – Biosimilars Still Niche Unclear Regulations for Biosimilars
8.1.3 Opportunities Patent Expiry for Branded Biologics Innovation – New Technology Driving Biosimilar Growth Focus on Biosimilar Monoclonal Antibodies and Insulin
8.1.4 Threats Stricter Regulations for Biosimilar Manufacturers Lawsuits – Patent Protection from Innovator Biologics Biobetters - Removing the Need for Biosimilars?
8.2 STEP Analysis of the Global Biosimilars Industry and Market, 2015-2025
8.2.1 Social Factors Global Healthcare – An Ambitious Aim?
8.2.2 Technological Factors Innovation Driven – Growing Manufacturing Efficiency Huge Technology Expertise Needed
8.2.3 Economic Factors Costly R&D for Biosimilar Development Healthcare Savings – Cutting Spending and Costs
8.2.4 Political Factors Government Influence – Funding for Biosimilar Industry?
9. Opinions from our Industry Survey
9.1 Mr Peter Keller, Chief Business Officer, Selecta Bioscience
9.1.1 Novel Technology Platform
9.1.2 Application with Drugs
9.1.3 Biosimilar Vaccines – Future Potential?
9.1.4 Future Strategies
9.1.5 Biosimilar Market Outlook
9.2 Industry Source from a Leading Indian Biopharmaceutical Company
9.2.1 Indian Pharmaceutical and Biosimilars Market Overview
9.2.2 Indian Patent Protection - Effect on Biosimilar Industry
9.2.3 Partnerships Among Biosimilar Companies
9.2.4 Future Developments in the Indian Biosimilars Market
10. Conclusions
10.1 Sandoz Retains the Top Spot
10.2 Market Leaders Among Biosimilar Manufacturers
10.3 Entrance of the Big Pharma Companies
10.4 Rise of Chinese and Indian Companies
10.5 Strong R&D Pipeline – Driver for Growth
10.6 Concluding Remarks
List of Tables
Table 1.1 Foreign Currency Exchange Rates: Average Exchange Rate to USD, 2015
Table 3.1Global Biosimilar Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2015-2025
Table 5.1 Revenue ($bn) of Selected Leading Biologics, 2014
Table 5.2 Humira Biologic Analysis, 2015
Table 5.3 Remicade Biologic Analysis, 2015
Table 5.4 Enbrel Biologic Analysis, 2015
Table 5.5 Aranesp Biologic Analysis, 2015
Table 5.6 Rituxan Biologic Analysis, 2015
Table 6.1 Visiongain’s Ranking of the Top 25 Biosimilar Manufacturers by Related Revenue ($bn), 2014
Table 6.2 Sandoz: Company Overview, 2015
Table 6.3 Teva: Company Overview, 2015
Table 6.4 Hospira: Company Overview, 2015
Table 6.5 Celltrion: Company Overview, 2015
Table 6.6 LG Life Sciences: Company Overview, 2015
Table 6.7 Biocon: Company Overview, 2015
Table 6.8 Mylan: Company Overview, 2015
Table 6.9 Qilu Pharmaceutical: Company Overview, 2015
Table 6.10 3SBio: Company Overview, 2015
Table 6.11 Bioton: Company Overview, 2015
Table 6.12 Dr. Reddy’s Laboratories: Company Overview, 2015
Table 6.13 Beijing ShuangLu Pharmaceutical: Company Overview, 2015
Table 6.14 Shanghai Fosun Pharmaceutical, 2015
Table 6.15 Wockhardt: Company Overview, 2015
Table 6.16 STADA Arzneimittel: Company Overview, 2015
Table 6.17 Probiomed: Company Overview, 2015
Table 6.18 Biosidus: Company Overview, 2015
Table 6.19 Ranbaxy: Company Overview, 2015
Table 6.20 Dong-A: Company Overview, 2015
Table 6.21 Tonghua Dongbao: Company Overview, 2015
Table 6.22 Reliance Life Sciences: Company Overview, 2015
Table 6.23 Intas Biopharmaceuticals: Company Overview, 2015
Table 6.24 Zydus Cadila: Company Overview, 2015
Table 6.25 Shanghai CP Guojian: Company Overview, 2015
Table 6.26 Emcure Pharmaceuticals: Company Overview, 2015
Table 6.27 Amgen: Company Overview, 2015
Table 6.28 Pfizer: Company Overview, 2015
Table 6.29 Merck KGaA: Company Overview, 2015
Table 6.30 Boehringer Ingelheim: Company Overview, 2015
Table 7.1 Impax Laboratories: Company Overview, 2015
Table 7.2 Bristol-Myers Squibb: Company Overview, 2015
Table 7.3 Merck & Co.: Company Overview, 2015
Table 7.4 Eli Lilly: Company Overview, 2015
Table 7.5 JCR Pharmaceuticals: Company Overview, 2015
Table 7.6 Nippon Kayaku: Company Overview, 2015
Table 7.7 Fujifilm Kyowa Kirin Biologics: Company Overview, 2015
Table 7.8 Daiichi Sankyo: Company Overview, 2015
Table 7.9 BioXpress Therapeutics: Company Overview, 2015
Table 7.10 Medice Arzneimittel Pütter: Company Overview, 2015
Table 7.11 Finox Biotech: Company Overview, 2015
Table 7.12 Gedeon-Richter: Company Overview & Analysis, 2015
Table 7.13 Egis Pharmaceuticals: Company Overview, 2015
Table 7.14 Actavis: Company Overview, 2015
Table 7.15 Bionovis: Company Overview, 2015
Table 7.16 Orygen Biotecnologia: Company Overview, 2015
Table 7.17 Recepta: Company Overview, 2015
Table 7.18 Biocad: Company Overview, 2015
Table 7.19 Shreya Life Sciences: Company Overview, 2015
Table 7.20 Cipla: Company Overview, 2015
Table 7.21 Shantha Biotechnics: Company Overview, 2015
Table 7.22 Zhejiang Hisun: Company Overview, 2015
Table 7.23 Innovent Biologics: Company Overview, 2015
Table 7.24 Shanghai Celgen Pharmaceuticals: Company Overview, 2015
List of Figures
Figure 1.1 Biosimilars Market Segmentation, 2015
Figure 3.1 Global Biosimilars Revenue Forecast ($bn), 2015-2025
Figure 3.2 Market Drivers for the Biosimilars Market, 2015
Figure 3.3 Market Restraints for the Biosimilars Market, 2015
Figure 4.1 Biosimilar Market Segmentation, 2015
Figure 5.1 Patent Expiration Dates of Some Original Branded Biologics
Figure 5.2 Biosimilar Adalimumab Pipeline Progress: Selected Companies, 2015
Figure 5.3 Biosimilar Infliximab Pipeline Progress: Selected Companies, 2015
Figure 5.4 Biosimilar Etanercept Pipeline Progress: Selected Companies, 2015
Figure 5.5 Biosimilar Darbepoetin alpha Pipeline Progress: Selected Companies, 2015
Figure 5.6 Biosimilar Rituximab Pipeline Progress: Selected Companies, 2015
Figure 6.1 Estimated Market Shares (%) of the Leading Biosimilar Manufacturers, 2014
Figure 6.2 Sandoz Biosimilar Revenue ($bn), 2013-2014
Figure 6.3 Sandoz Biosimilar Pipeline Progress, 2015
Figure 6.4 Teva Biosimilar Pipeline Progress, 2015
Figure 6.5 Hospira Biosimilar Pipeline Progress, 2015
Figure 6.6 Celltrion Biosimilar Pipeline Progress, 2015
Figure 6.7 LG Life Sciences Biosimilar Pipeline Progress, 2015
Figure 6.8 Biocon Biosimilar Pipeline Progress, 2015
Figure 6.9 Mylan Biosimilar Pipeline Progress, 2015
Figure 6.10 3SBio Biosimilar Pipeline Progress, 2015
Figure 6.11 Dr. Reddy’s Laboratories Pipeline Progress, 2015
Figure 6.12 Beijing ShuangLu Pharmaceutical Biosimilar Pipeline Progress, 2015
Figure 6.13 Shanghai Fosun Pharmaceuticals Biosimilar Pipeline, 2015
Figure 6.14 Wockhardt Biosimilar Pipeline Progress, 2015
Figure 6.15 STADA Biosimilar Pipeline Progress
Figure 6.16 Biosidus Biosimilar Pipeline Progress, 2015
Figure 6.17 Dong-A Biosimilar Pipeline Progress, 2015
Figure 6.18 Tonghua Dongbao Biosimilar Pipeline Progress, 2015
Figure 6.19 Reliance Life Sciences Biosimilar Pipeline Progress, 2015
Figure 6.20 Intas Biopharmaceuticals Biosimilar Pipeline Progress, 2015
Figure 6.21 Zydus Cadila Biosimilar Pipeline Progress, 2015
Figure 6.22 Boehringer Ingelheim Biosimilar Pipeline Progress, 2015
Figure 7.1 Merck & Co. Biosimilar Pipeline Progress, 2015
Figure 7.2 Eli Lilly Biosimilar Pipeline Progress, 2015
Figure 7.3 JCR Pharmaceutical Biosimilar Pipeline Progress, 2015
Figure 7.4 Fujifilm Kyowa Kirin Biologics Biosimilar Pipeline Progress, 2015
Figure 7.5 Daiichi Sankyo Biosimilar Pipeline Progress, 2015
Figure 7.6 Actavis Biosimilar Pipeline Progress, 2015
Figure 7.7 Biocad Biosimilar Pipeline Progress, 2015
Figure 8.1 SWOT Analysis of the Biosimilars Market, 2015
Figure 8.2 STEP Analysis of the Biosimilars Market, 2015
Figure 10.1 Leaders in the Biosimilars Market: Estimated Revenues ($bn), 2014

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook